In this casebased module Tanya Gupta MD reviews key data on integrating immune checkpoint inhibitorbased therapy into treatment of earlystage triplenegative breast cancer
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/icis-for-ebc/18941-33769
- Start Date: 2024-05-13 05:00:00
- End Date: 2024-05-13 05:00:00
- Credit Details: IPCE Credits: 0.5 hours
AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 25000.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 30000.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 48756.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest